scholarly journals Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part II

2015 ◽  
Vol 6 (3) ◽  
pp. 58-69
Author(s):  
M. G Bubnova
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Cardiovascular Events ◽  
Clinical Characteristics ◽  
Angiotensin Ii Receptor ◽  
Treatment Of Hypertension ◽  
Receptor Blockers ◽  
Azilsartan Medoxomil ◽  
Term Management

The article discusses the problem of the use for the treatment of hypertension combination therapy. Advantages of application as a component of chlorthalidone therapy are discussed. Proofs of its effectiveness in lowering both blood pressure and risk of cardiovascular events compared with hydrochlorothiazide are stated. Anti-hypertensive effectiveness of one of the last appeared on the pharmacological market of receptor-blockers like angiotensin II azilsartan medoxomil in combination with chlorthalidone is discussed as well.

scholarly journals Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part I

2015 ◽  
Vol 6 (2) ◽  
pp. 69-80
Author(s):  
M. G Bubnova
Keyword(s):  
Angiotensin Ii ◽  
Clinical Characteristics ◽  
Antihypertensive Drugs ◽  
Antihypertensive Efficacy ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Blockers ◽  
Azilsartan Medoxomil ◽  
Term Management

This article deals withthe overview of the pharmacological characteristics of one class of antihypertensive drugs - angiotensin II receptor antagonists (ARA II) and new member of this class - azilsartan medoxomil (Edarbi®).We have analyzed the antihypertensive efficacy of different ARA, as well as azilsartan medoxomil efficacyin case of monotherapy and in comparison with other ARA and angiotensin-converting enzyme inhibitorsamong different groups of patients.The article describes the pleiotropic effects of azilsartan medoxomil, discovered nowadays.

scholarly journals Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria

2011 ◽  
Vol 12 (1S) ◽  
pp. 9-17
Author(s):  
Francesco Vittorio Costa
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Cardiovascular Disorder ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Renal Protection ◽  
Receptor Blockers ◽  
Blood Pressure Goals

The search for a more specific and complete blockade of the hypertensive effects of angiotensin and of better tolerability than ACE-inhibitors has led to the development of angiotensin II receptor blockers (ARBs). ARBs have been evaluated in several large studies in terms of efficacy and safety in reducing blood pressure, as well as for cardiovascular and renal protection. Among angiotensin II receptor blockers, valsartan and losartan have the greatest number of therapeutic indications. In light of the costs related to cardiovascular disorder valsartan represents a potential long-term health cost saving strategy. Furthermore valsartan shows one of the lowest costs for patient achieving blood pressure goals and the higher level of persistence in its class.

Sign in / Sign up

Export Citation Format

Share Document